IKT vs ROK · $215.2M cap vs P/E 48, rev $8.34B
Inhibikase Therapeutics Inc (IKT) versus Rockwell Automation Inc (ROK) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Rockwell Automation Inc (ROK) is a specialty industrial machinery company listed on NYSE.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
Latest reported ROK revenue for 2025-09-30 was $8.34B. Net income was $749.0M. ROK currently screens at market cap $51.04B and trailing P/E 47.5.
IKT currently screens at market cap $215.2M. ROK currently screens at market cap $51.04B and trailing P/E 47.5.
Not investment advice. Open the IKT and ROK stock pages for the full models.
Not investment advice.